Elvitegravir/cobicistat pharmacokinetics in pregnant and postpartum women with HIV

Abstract

Standard elvitegravir and cobicistat dosing during pregnancy results in significantly lower exposure which may increase the risk of virologic failure and mother-to-child transmission. Additional studies are needed to optimize elvitegravir and cobicistat dosing regimens in pregnant women.